
Quarterly report 2023-Q2
added 08-08-2023
Eagle Pharmaceuticals Cash Flow 2011-2025 | EGRX
Annual Cash Flow Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
50.7 M | 28.2 M | 49.5 M | 56 M | 52.4 M | 58.9 M | 53.2 M | -9.72 M | -13.8 M | -5.88 M | -15.5 M | - |
Depreciation & Amortization |
646 K | 764 K | 872 K | 972 K | 1.16 M | 932 K | 641 K | 112 K | 104 K | 135 K | 240 K | - |
Accounts Payables |
19 M | 16.4 M | 6.27 M | 5.46 M | 9.92 M | 12 M | 14.7 M | 3.86 M | 3.5 M | - | - | - |
Accounts Receivables |
72.4 M | 41.1 M | 51.1 M | 48 M | 66.5 M | 53.8 M | 42.2 M | 26.3 M | 12 M | - | - | - |
Total Inventories |
47.8 M | 21.9 M | 8.08 M | 6.57 M | 8.3 M | 5.12 M | 2.74 M | 15 M | 1.24 M | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -33.5 M | - | 13.1 M | 26.4 M | -16.6 M | - | 20.1 M | 19.1 M | 10.5 M | - | 29.7 M | 24.1 M | 3.16 M | - | 59.2 M | 48.6 M | 26.2 M | - | 14.3 M | 10.6 M | 4.92 M | - | 33 M | 25.1 M | -12.4 M | - | 13.7 M | 484 K | 3.11 M | - | 7.08 M | 13.7 M | 25.8 M | -7.88 M | -13.9 M | -6.74 M | -2.07 M | 23 K | -5.56 M | -2.83 M | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
100 K | 100 K | - | 200 K | 200 K | 200 K | - | 200 K | 200 K | 200 K | - | 196 K | 209 K | 251 K | - | 241 K | 241 K | 242 K | - | 918 K | 683 K | 341 K | - | 657 K | 432 K | 196 K | - | 461 K | 296 K | 140 K | - | 31 K | 22 K | 12 K | 13 K | 73 K | 51 K | 29 K | 31 K | 105 K | 78.5 K | - | - | - | - | - | - | - | - | - |
Accounts Payables |
15.8 M | 17.1 M | 19 M | 13.2 M | 20 M | 14.5 M | 16.4 M | 12.7 M | 11.1 M | 12.6 M | 6.27 M | 6.27 M | 6.27 M | 6.27 M | 5.46 M | 5.46 M | 5.46 M | 5.46 M | 9.92 M | 9.92 M | 9.92 M | 9.92 M | 12 M | 12 M | 12 M | 12 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 3.86 M | 3.86 M | 3.86 M | 3.86 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | - | 1.19 M | 1.19 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
115 M | 115 M | 72.4 M | 96.9 M | 85.9 M | 131 M | 41.1 M | 45.3 M | 52.7 M | 44.9 M | 51.1 M | 50.7 M | 50.7 M | 50.7 M | 48 M | 48 M | 48 M | 48 M | 66.5 M | 66.5 M | 66.5 M | 66.5 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 42.2 M | 42.2 M | 42.2 M | 42.2 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 12 M | 12 M | 12 M | 12 M | - | 5.12 M | 5.12 M | - | - | - | - | - | - | - | - | - |
Total Inventories |
42.5 M | 44.1 M | 47.8 M | 63.9 M | 57.7 M | 24.8 M | 21.9 M | 9.32 M | 8.29 M | 6.86 M | 8.08 M | 8.08 M | 8.08 M | 8.08 M | 6.57 M | 6.57 M | 6.57 M | 6.57 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 5.12 M | 5.12 M | 5.12 M | 5.12 M | 2.74 M | 2.74 M | 2.74 M | 2.74 M | 15 M | 15 M | 15 M | 15 M | 1.24 M | 1.24 M | 1.24 M | 1.24 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Eagle Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Drug manufacturers sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
$ 0.73 | -3.6 % | $ 51.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.7 | -2.59 % | $ 183 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
$ 3.07 | -6.25 % | $ 1.6 B | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
$ 5.11 | -5.46 % | $ 86.3 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
$ 12.37 | 8.32 % | $ 633 M | ||
|
Evoke Pharma
EVOK
|
$ 10.96 | 0.09 % | $ 36.6 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.43 | 0.3 % | $ 2.04 B | ||
|
Evolus
EOLS
|
$ 7.18 | 1.99 % | $ 445 M | ||
|
Harrow Health
HROW
|
$ 46.29 | -1.64 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
$ 6.9 | -0.36 % | $ 2.52 B | ||
|
Organogenesis Holdings
ORGO
|
$ 4.78 | -0.83 % | $ 629 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Pacira BioSciences
PCRX
|
$ 26.61 | 1.22 % | $ 1.23 B | ||
|
OrganiGram Holdings
OGI
|
$ 1.8 | -6.19 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 3.11 | 22.92 % | $ 43.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Rockwell Medical
RMTI
|
$ 0.88 | -5.3 % | $ 20.5 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.55 | -1.11 % | $ 4.41 M | ||
|
Solid Biosciences
SLDB
|
$ 5.75 | -2.04 % | $ 235 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.34 | 6.91 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
$ 12.77 | -2.78 % | $ 1.75 B | ||
|
ProPhase Labs
PRPH
|
$ 0.11 | -0.35 % | $ 1.74 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
$ 1.99 | -9.95 % | $ 3.37 M | ||
|
Veru
VERU
|
$ 2.4 | -0.83 % | $ 324 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
$ 1.19 | -0.83 % | $ 5.13 M | ||
|
SCYNEXIS
SCYX
|
$ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 11.01 | -9.4 % | $ 6.8 B | ||
|
TherapeuticsMD
TXMD
|
$ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
$ 11.68 | 0.29 % | $ 14.2 B |